Market Closed -
Nasdaq
04:30:00 2024-05-15 pm EDT
|
5-day change
|
1st Jan Change
|
0.4065
USD
|
+6.44%
|
|
-5.24%
|
-29.30%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
58.82
|
42.61
|
4.326
|
11.07
|
7.828
|
-
|
-
|
Enterprise Value (EV)
1 |
58.82
|
42.61
|
4.326
|
11.07
|
7.828
|
7.828
|
7.828
|
P/E ratio
|
-3.58
x
|
-2.66
x
|
-0.21
x
|
-2.05
x
|
-1.51
x
|
-1.85
x
|
-0.83
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
7,832
|
8,330
|
18,330
|
19,258
|
19,258
|
-
|
-
|
Reference price
2 |
7.510
|
5.115
|
0.2360
|
0.5750
|
0.4065
|
0.4065
|
0.4065
|
Announcement Date
|
3/18/21
|
3/17/22
|
3/14/23
|
2/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-
|
-15.64
|
-12.32
|
-5.447
|
-6
|
-8.264
|
-12.6
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-
|
-15.96
|
-12.25
|
-5.296
|
-5.9
|
-8.214
|
-17.49
|
Net income
1 |
-10.35
|
-15.96
|
-12.25
|
-5.296
|
-5.9
|
-8.214
|
-17.49
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-2.100
|
-1.920
|
-1.110
|
-0.2800
|
-0.2700
|
-0.2200
|
-0.4900
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/18/21
|
3/17/22
|
3/14/23
|
2/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
|
-4.111
|
-4.188
|
-3.961
|
-3.672
|
-2.592
|
-2.09
|
-1.557
|
-1.477
|
-1.274
|
-1.138
|
-
|
-1.4
|
-1.6
|
-1.7
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
|
-4.11
|
-4.511
|
-3.96
|
-3.667
|
-2.576
|
-2.045
|
-1.517
|
-1.441
|
-1.235
|
-1.103
|
-
|
-1.3
|
-1.6
|
-1.7
|
Net income
|
-4.11
|
-4.511
|
-3.96
|
-3.667
|
-2.576
|
-2.045
|
-1.517
|
-1.441
|
-1.235
|
-1.103
|
-
|
-1.3
|
-1.6
|
-1.7
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.4900
|
-0.5400
|
-0.4800
|
-0.4400
|
-0.2800
|
-0.1100
|
-0.0800
|
-0.0800
|
-0.0600
|
-0.0600
|
-0.0700
|
-0.0700
|
-0.0600
|
-0.0700
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/11/21
|
3/17/22
|
5/12/22
|
8/11/22
|
11/14/22
|
3/14/23
|
5/12/23
|
8/10/23
|
11/13/23
|
2/29/24
|
5/9/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/18/21
|
3/17/22
|
3/14/23
|
2/29/24
|
-
|
-
|
-
|
Last Close Price
0.4065
USD Average target price
2.2
USD Spread / Average Target +441.21% Consensus |
1st Jan change
|
Capi.
|
---|
| -29.30% | 7.83M | | +7.52% | 113B | | +11.38% | 106B | | -12.64% | 22.22B | | +0.44% | 22.27B | | -4.18% | 19.43B | | -37.85% | 17.87B | | -8.58% | 17.24B | | +37.41% | 12.52B | | -23.95% | 8.34B |
Bio Therapeutic Drugs
|